Zevra Therapeutics Reports 53% Revenue Growth to $39.7 Million in Q2 2026

Zevra Therapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with net revenues for the second quarter of 2026 reaching $39.7 million, a 53% increase from $25.9 million in the same period last year. For the first half of 2026, total revenues amounted to $75.9 million, compared to $46.3 million in the first half of 2025, marking a 64% increase. The company attributed this growth primarily to increased sales of its lead product, MIPLYFFA, which generated $30.2 million in the second quarter and $54.9 million in the first half of 2026, up from $21.5 million and $38.6 million, respectively, in the prior year.

Zevra's financial results also reflected a notable shift in profitability. The company reported a net income of $8.8 million for the second quarter of 2026, a decrease from $74.7 million in the same quarter of 2025, largely due to a one-time gain from the sale of a priority review voucher (PRV) in the previous year. For the first half of 2026, net income was $46.6 million, down from $71.6 million in the first half of 2025. The decrease in net income was also influenced by increased operating expenses, including research and development costs, which rose to $4.5 million in the second quarter, up from $3.4 million a year earlier.

In terms of strategic developments, Zevra completed the acquisition of Acer Therapeutics in November 2023, which included OLPRUVA, a treatment for urea cycle disorders, and a pipeline of investigational products. The company also entered into a settlement agreement with Commave Therapeutics in March 2026, resulting in a gain of $43.3 million from the sale of certain assets related to its SDX portfolio. This strategic move is part of Zevra's broader plan to enhance its product offerings and market presence in rare diseases.

Operationally, Zevra has made strides in expanding its customer base and product adoption. As of June 30, 2026, the company reported 184 enrollments for MIPLYFFA under its global expanded access program, indicating a growing interest in its products. The company continues to focus on building its commercial capabilities and enhancing awareness of its therapies among healthcare providers and patients. Additionally, Zevra's cash and cash equivalents increased significantly to $145.3 million as of June 30, 2026, up from $62.4 million at the end of 2025, providing a solid financial foundation for ongoing operations and future growth initiatives.

Looking ahead, Zevra anticipates continued investment in its research and development efforts, particularly for its clinical-stage asset celiprolol, which is currently in a Phase 3 trial for Vascular Ehlers-Danlos syndrome. The company expects to incur significant expenses as it builds its commercial capabilities and seeks regulatory approvals for its product candidates. While Zevra has recently generated positive cash flows from operations, it acknowledges the potential for fluctuations in expenses and revenues, emphasizing the need for ongoing financial management and strategic planning to support its growth objectives.